EASD 2026 brought phase 3 retatrutide data, new CagriSema results, and an amylin plus tirzepatide combination. The field is moving beyond single-receptor agonism.
More-
Incretin Research Update: Retatrutide, CagriSema and Amylin Combinations Lead EASD 2026
-
Ten Weeks After the Advisory Vote, FDA Peptide Compounding Decision Remains Pending
Ten weeks after the PCAC recommended six peptides for the 503A Bulks List, the FDA has not acted. States are splitting, enforcement continues, and verification matters more than ever.
More -
FDA Panel Recommends Six of Seven Peptides for Compounding, Rejects Emideltide
The FDA’s Pharmacy Compounding Advisory Committee closed its two-day meeting on July 24 having recommended six of the seven peptides under review for the Section 503A Bulk Drug Substances List. Only emideltide, also known as DSIP, failed to pass, falling 6 to 7 with one abstention. On July 23, the committee voted 8 to 6, …
More -
FDA Warns San Diego Pharmacist Over Unapproved Retatrutide and Tirzepatide Sales
Bernard Gramlich, founder of GRAM peptides and a former Rancho Santa Fe pharmacist, has agreed to stop selling retatrutide and tirzepatide injections online after receiving a formal warning letter from the FDA in March, according to reporting from 10News San Diego. The products were sold alongside bacteriostatic water for injection, despite the site’s stated research …
More -
RFK, the FDA, and Seven Peptides: What to Expect from the July 2026 PCAC Review
Industry Pulse › RFK and the FDA July 2026 Peptide Decision May 24, 2026 · Regulatory Research Use Only. This article analyzes upcoming FDA regulatory activity in the context of research peptide supply chains. Genevium peptides are intended strictly for laboratory research purposes. Not approved for human consumption, clinical, therapeutic, veterinary, or diagnostic use. For …
More -
What the Peptide Sciences Shutdown Revealed: A Supplier-Side Analysis of Research Peptide Operations in 2026
Industry Pulse › What the Peptide Sciences Shutdown Revealed May 23, 2026 · Research In March 2026, Peptide Sciences voluntarily ceased operations. The company had been one of the largest U.S. research peptide suppliers for more than a decade, with an estimated $7.4 million in monthly revenue and a customer base spanning academic laboratories, independent …
More -
The FDA Peptide Reclassification of 2026: What Actually Changed, What’s Pending, and What It Means for Research Suppliers
Industry Pulse › The FDA Peptide Reclassification of 2026 May 23, 2026 · Regulatory In the first half of 2026, the FDA built and deployed a framework. The framework is clinical need, and it is now the lens through which every peptide compounding question will be evaluated going forward. Three regulatory actions between February and …
More -
Peptide Storage Methodology
Research Hub › Research Methodology › Peptide Storage Methodology Research Use Only. The information on this page summarizes published peptide research for laboratory and educational reference. The compounds discussed are intended exclusively for in vitro and non-clinical research. Nothing on this page constitutes medical advice or describes human use, diagnosis, treatment, or therapeutic application. Overview …
More